Malignant Pleural Effusion Market

Malignant Pleural Effusion Market Snapshot (2023 to 2033)

The global malignant pleural effusion market is expected to garner a market value of USD 4.5 Billion in 2023 and is expected to accumulate a market value of USD 8.06 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusion treatment with different types of techniques in the current market works as a driver for the market. The market for Malignant Pleural Effusion registered a CAGR of 4% in the historical period 2018 to 2022.

Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period. Recent epidemiological data from WHO suggests that approximately more than one million pleural effusions are diagnosed in the United States each year.

Report Attribute	Details
Expected Market Value (2023)	USD 4.5 Billion
Anticipated Forecast Value (2033)	USD 8.06 Billion
Projected Growth Rate (2023 to 2033)	6% CAGR

2018 to 2022 Malignant Pleural Effusion Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights. the market for Malignant Pleural Effusion reflected a value of 4% during the historical period, 2018 to 2022. Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.

Selling campaigns initiated by global players are growing the market progressively. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of pleural effusions is fuelling market growth. Thus, the market for Malignant Pleural Effusion is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Malignant Pleural Effusion Market?

Increasing Incidence of Malignant Pleural Effusion disease post covid-19 pandemic to push the market growth

The increasing prevalence of Malignant Pleural Effusion disease is one of the biggest drivers of the market. After The covid-19 pandemic hit the world, various research was conducted to find a correlation between Covid-19 infection and pleural effusion.

For instance, the article “Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis” published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease.

Pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. Considering these in-depth studies, the pandemic showed a considerable impact on the market studied.

What are the Challenges Faced by the Malignant Pleural Effusion Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Malignant Pleural Effusion, less awareness of Malignant Pleural Effusion disease, and insubstantial treatment options are hampering the market growth.

Region-Wise Insights

How is the Market for Malignant Pleural Effusion Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling the growth of Malignant Pleural Effusion in Asia Pacific

The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of malignant pleural effusion in the region.

Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the Pleural effusions treatment market worldwide.

What are the Factors Boosting the Market for Malignant Pleural Effusion in North America?

High Prevalence of various diseases shaping the landscape for Malignant Pleural Effusion in North America

North America is anticipated to acquire a market share of about 45% in the forecast period. This growth is attributable to the rising prevalence of pleural effusions in the region. An article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people.

This ever-widening burden of the condition on the healthcare facilities is creating demand for the treatment globally, expected to fuel the market growth during the analysis period. Furthermore, the rising geriatric population is leading to an increase in the prevalence of various diseases, growing the health and economic burden.

As per the American Heart Association data updated in April 2022, nearly 115 million people in have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of various diseases creates the risk of pleural effusions among the target population in the United States.

Start-Up in the Malignant Pleural Effusion Market

Key start-up players in the Malignant Pleural Effusion market are-

• SensoriumLab is a Polish company that offers a user-friendly and non-invasive diagnostic system for the assessment of pleural effusion (water on lungs). The device makes it possible to monitor patients remotely, and the monitoring can even be handled by non-professionals.
• BIORIDIS is a biotech company founded in Bologna, Italy in 2016 that is working to reduce costs, increase productivity and improve technical performance in biomedical Research and Development and molecular diagnostics. The company’s objective is the development, production, and marketing of innovative kits for nucleic acid (DNA, RNA) analysis for biomedical Research and Development and molecular diagnostics applications, especially for small RNAs (e.g. microRNAs).
• BrainScan Sp. z o. o. is a Polish start-up using artificial intelligence to improve the efficiency of interpretations of Brain CT Scans. The company provides automatic search for similarly computed tomography (CT) or magnetic resonance imaging (MRI) scans in large data sets. It searches for medical cases that are similar to a given scan or region of interest.

Market Competition

Key players in the Malignant Pleural Effusion market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.

• In September 2021, BDR Pharma launched BIAPENEM to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. Biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid).
• In April 2022, the study titled “IFN-γ Combined with T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites” was registered in ClinicalTrials.gov for Malignant Pleural Effusion.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 4.5 Billion
Market Value in 2033	USD 8.06 Billion
Growth Rate	CAGR of 6% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment, End User, Diagnosis, Region
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Middle East & Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, BENELUX, France, Germany, Italy, Nordics, Spain, The UK, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled	B. Braun SE; Becton, Dickinson, and Company; Bicakcilar; Biometrix; Cook Medical; Grena; Redax; Rocket Medical; Smith Medical; Taiho Pharmaceutical Co. Ltd.
Customization	Available Upon Request

Key Segments Profiled in the Malignant Pleural Effusion Industry Survey

By Diagnosis:

• Imaging Tests
• Pleural Thoracentesis
• Pleural Fluid Cytology
• Immunohistochemical Tests
• Pleural Biopsy
• Thoracoscopy/Pleuroscopy

By End User:

• Hospitals
• Ambulatory Clinics
• Others

By Treatment:

• Systemic Therapy
• Therapeutic Thoracentesis
• Thoracic Drainage and Pleurodesis
• Indwelling Pleural Catheter

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific
• Middle East & Africa (MEA)

Frequently Asked Questions

At what rate did the Malignant Pleural Effusion market flourish from 2017 to 2022?

From 2017 to 2022, the Malignant Pleural Effusion market grew at a CAGR of 4%.

What will be the growth rate of the global Malignant Pleural Effusion market during the forecast period?

The global Malignant Pleural Effusion market is expected to grow with a 6% CAGR from 2023 to 2033.

What will be the projected market size of the Malignant Pleural Effusion market by 2033?

As of 2033, the Malignant Pleural Effusion market is expected to reach USD 8.06 Billion

Which End-Use segment is expected to dominate the global Malignant Pleural Effusion market during 2033?

According to the FMI analysis, hospitals account for the largest market share.

How is the North America Malignant Pleural Effusion market projected to grow in 2033?

North America is expected to possess a 45% market share for the Malignant Pleural Effusion market.

How is the Asia Pacific Malignant Pleural Effusion market projected to grow in 2033?

The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.